Clinical Scorecard: Leflunomide eyed for steroid-sparing ICANS care
At a Glance
| Category | Detail |
|---|---|
| Condition | Immune effector cell-associated neurotoxicity syndrome (ICANS) |
| Key Mechanisms | Mitochondrial dysfunction and neuroinflammation feedforward loop |
| Target Population | Patients undergoing CAR T-cell therapy |
| Care Setting | Clinical evaluation of mitochondrial-targeting drugs |
Key Highlights
- Leflunomide identified as a prototype candidate for ICANS management
- Mitochondrial dysfunction may amplify neuroinflammation
- Current treatments include corticosteroids, which may lead to steroid-refractory disease
- Leflunomide's mechanism involves DHODH inhibition affecting mitochondrial function
- Proposed evaluation pathway includes preclinical studies and randomized clinical trials
Guideline-Based Recommendations
Diagnosis
- ICANS is characterized by systemic cytokine elevation followed by CNS inflammatory amplification
Management
- Corticosteroids are the mainstay treatment but may not be effective for all patients
Monitoring & Follow-up
- Careful timing of leflunomide initiation relative to CAR T-cell infusion is recommended
Risks
- Potential impairment of CAR T-cell expansion due to DHODH inhibition
Patient & Prescribing Data
Patients with ICANS post-CAR T-cell therapy
Leflunomide's active metabolite, teriflunomide, shows CNS exposure and has been used in other inflammatory conditions
Clinical Best Practices
- Consider uridine supplementation to rescue DHODH inhibition effects
- Evaluate mitochondrial-targeting drugs in a staged approach from preclinical to clinical trials
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
